Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis

Abstract Background Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) for which several new treatment options were recently introduced. Among them is the monoclonal anti-CD52 antibody alemtuzumab that depletes mainly B cells and T cells in the immune periphe...

Description complète

Détails bibliographiques

Auteurs principaux:	Micha Simon, Rojda Ipek, György A. Homola, Damiano M. Rovituso, Andrea Schampel, Christoph Kleinschnitz, Stefanie Kuerten
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2018-08-01
Collection:	Journal of Neuroinflammation
Sujets:	Alemtuzumab B cells CD52 CNS EAE MS
Accès en ligne:	http://link.springer.com/article/10.1186/s12974-018-1263-9
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!